We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Ovarian Cancer Risk May Be Paternally Inherited

By LabMedica International staff writers
Posted on 01 Mar 2018
Print article
Image: Diagrams for X-linked inheritance when cancer status is specific to women (all carrier men are effectively disease censored). Two family patterns with a pair of first-degree affected women are the maternal grandmother (MGM) family and the paternal grandmother (PGM) family (Photo courtesy of Roswell Park Cancer Institute).
Image: Diagrams for X-linked inheritance when cancer status is specific to women (all carrier men are effectively disease censored). Two family patterns with a pair of first-degree affected women are the maternal grandmother (MGM) family and the paternal grandmother (PGM) family (Photo courtesy of Roswell Park Cancer Institute).
A history of ovarian cancer among first-order relatives remains the strongest and best-characterized predictor of ovarian cancer risk and a main determinant of genetic testing referral.

The evidence for a monogenic, autosomal dominant mode of inherited risk dates to the pre- breast cancer 1, early onset gene (BRCA) era where studies focused on assessing heritability using affected first-order and second-order female relatives.

Scientists at Roswell Park Cancer Institute (Buffalo, NY, USA) and their colleagues first identified 3,499 grandmother-granddaughter pairs from a familial ovarian cancer registry that encompassed information on more than 50,000 individuals from 2,600 families collected over several decades. They whittled this set down to the 892 pairs, providing clues to ovarian cancer risk transmission, which included 157 granddaughters with ovarian cancer.

In an effort to tease out the basis of this X-linked inheritance, the scientists did exome sequencing on 159 BRCA1/2 mutation-negative women from the registry, focusing on germline X chromosome and BRCA1 coding sequences. The group included 49 ovarian cancer-affected women with affected mothers, 46 cases who had an affected sister and unaffected mother, and seven ovarian cancer-affected women with an affected sister and mother.

The team found that overlapping ovarian cancer diagnoses were more common in the paternal grandmother-granddaughter pairs, where the cancer rate was more than 28% than in the pairs involving maternal grandmothers and their granddaughters. The latter pairs had an ovarian cancer rate just shy of 14%. The presence of ovarian cancer in a paternal grandmother, but not a maternal grandmother, coincided with earlier age of onset in affected granddaughters. They tracked down a missense mutation in the MAGE Family Member C3 (MAGEC3), a gene previously put forward as a potential X-linked tumor suppressor. The variant was in linkage disequilibrium with other nearby variants, suggesting there might be an alternative causal variant or a related haploblock in the X chromosome region identified.

The authors concluded that they had demonstrated that a genetic locus on the X-chromosome contributes to ovarian cancer risk. An X-linked pattern of inheritance has implications for genetic risk stratification. Women with an affected paternal grandmother and sisters of affected women are at increased risk for ovarian cancer.

Kevin H. Eng, PhD, an assistant professor of oncology and the lead author said. “Our study may explain why we find families with multiple affected daughters: because a dad's chromosomes determine the sex of his children, all of his daughters have to carry the same X-chromosome genes.” The study was published on February 15, 2018, in the journal PLOS Genetics.

Related Links:
Roswell Park Cancer Institute

Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
TETANUS Test
TETANUS VIRCLIA IgG MONOTEST
New
Centrifuge
Hematocrit Centrifuge 7511M4

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.